The Journal of Heart and Lung Transplantation
Volume 23, Issue 6 , Pages 701-708 , June 2004

Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study)

This study was presented as a Late Breaking Clinical Trial at the American College of Cardiology 51st Annual Scientific Session, Atlanta, GA, March 19, 2002.

  • Michael Phillips, MD, FACP

      Affiliations

    • Menssana Research, Inc. Fort Lee, New Jersey, USA
    • Department of Medicine, New York Medical College, Valhalla, New York, USA
    • Corresponding Author InformationReprint requests: Michael Phillips, MD, FACP, Menssana Research, Inc., 1 Horizon Road, Suite 1415, Fort Lee, NJ 07024, USA.
    • ,
  • John P Boehmer, MD

      Affiliations

    • Department of Medicine, M.S. Hershey Medical Center of the Pennsylvania State University School of Medicine, Hershey, Pennsylvania, USA
    • ,
  • Renee N Cataneo, MA

      Affiliations

    • Menssana Research, Inc. Fort Lee, New Jersey, USA
    • ,
  • Taseer Cheema, MD

      Affiliations

    • Menssana Research, Inc. Fort Lee, New Jersey, USA
    • ,
  • Howard J Eisen, MD

      Affiliations

    • Temple University Hospital, Philadelphia, Pennsylvania, USA
    • ,
  • John T Fallon, MD, PhD, FAHA

      Affiliations

    • Department of Pathology, Mount Sinai Medical Center, New York, USA
    • ,
  • Peter E Fisher, MD

      Affiliations

    • Columbia Presbyterian Medical Center, New York, New York, USA
    • ,
  • Alan Gass, MD

      Affiliations

    • Department of Medicine, Mount Sinai Medical Center, New York, New York, USA
    • ,
  • Joel Greenberg, BS

      Affiliations

    • Menssana Research, Inc. Fort Lee, New Jersey, USA
    • ,
  • Jon Kobashigawa, MD

      Affiliations

    • University of California Los Angeles Medical Center, Los Angeles, California, USA
    • ,
  • Donna Mancini, MD

      Affiliations

    • Columbia Presbyterian Medical Center, New York, New York, USA
    • ,
  • Barry Rayburn, MD

      Affiliations

    • University of Alabama at Birmingham, Birmingham, Alabama, USA
    • ,
  • Mark J Zucker, MD

      Affiliations

    • Newark Beth Israel Medical Center, Newark, New Jersey, USA

Received 22 January 2003 ,Revised 18 July 2003 ,Accepted 23 July 2003.

References 

  1. Edwards LB. Personal communication. Richmond, VA: United Network for Organ Sharing ISHLT Transplant Registry.
  2. Winters GL, McManus BM. Consistencies and controversies in the application of the International Society for Heart and Lung Transplantation working formulation for heart transplant biopsy specimens. Rapamycin Cardiac Rejection Treatment Trial Pathologists. J Heart Lung Transplant. 1996;15:728–735
  3. Khaw BA, Narula J. Antibody imaging in the evaluation of cardiovascular diseases. J Nucl Cardiol. 1994;1:457–476
  4. Moran AM, Lipshultz SE, Rifai N, et al.  Non-invasive assessment of rejection in pediatric transplant patients (Serologic and echocardiographic prediction of biopsy-proven myocardial rejection). J Heart Lung Transplant. 2000;19:756–764
  5. Sobotka PA, Gupta DK, Lansky DM, Costanzo MR, Zarling EJ. Breath pentane is a marker of acute cardiac allograft rejection. J Heart Lung Transplant. 1994;13:224–229
  6. Schimke I, Schikora M, Meyer R, et al.  Oxidative stress in the human heart is associated with changes in the antioxidative defense as shown after heart transplantation. Mol Cell Biochem. 2000;204:89–96
  7. Kneepkens CM, Ferreira C, Lepage G, Roy CC. The hydrocarbon breath test in the study of lipid peroxidation (Principles and practice). Clin Invest Med. 1992;15:163–186
  8. Kneepkens CM, Lepage G, Roy CC. The potential of the hydrocarbon breath test as a measure of lipid peroxidation. Free Radic Biol Med. 1994;17:127–160
  9. Phillips M. Breath tests in medicine. Sci Am. 1992;267:74–79
  10. Holt DW, Johnston A, Ramsey JD. Breath pentane and heart rejection. J Heart Lung Transplant. 1994;13:1147–1148
  11. Kohlmuller D, Kochen W. Is n-pentane really an index of lipid peroxidation in humans and animals? A methodological reevaluation. Anal Biochem. 1993;210:268–276
  12. Cailleux A, Allain P. Is pentane a normal constituent of human breath?. Free Radic Res Commun. 1993;18:323–327
  13. Phillips M, Greenberg J, Sabas M. Alveolar gradient of pentane in normal human breath. Free Radic Res. 1994;20:333–337
  14. Phillips M. Method for the collection and assay of volatile organic compounds in breath. Anal Biochem. 1997;247:272–278
  15. Phillips M, Herrera J, Krishnan S, Zain M, Greenberg J, Cataneo RN. Variation in volatile organic compounds in the breath of normal humans. J Chromatogr B Biomed Sci Appl. 1999;729:75–88
  16. Phillips M, Greenberg J, Cataneo RN. Effect of age on the profile of alkanes in normal human breath. Free Radic Res. 2000;33:57–63
  17. Phillips M, Cataneo RN, Greenberg J, Gunawardena R, Naidu A, Rahbari-Oskoui F. Effect of age on the breath methylated alkane contour, a display of apparent new markers of oxidative stress. J Lab Clin Med. 2000;136:243–249
  18. Billingham ME, Cary NR, Hammond ME, et al.  A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection (Heart rejection study group. the international society for heart transplantation). J Heart Transplant. 1990;9:587–593
  19. SPSS for Windows, standard version. Cary, NC: SPSS; 1998.
  20. Cargnoni A, Ceconi C, Bernocchi P, et al.  Changes in oxidative stress and cellular redox potential during myocardial storage for transplantation (Experimental studies). J Heart Lung Transplant. 1999;18:478–487
  21. Grunenfelder J, Miniati DN, Murata S, et al.  Upregulation of Bcl-2 through caspase-3 inhibition ameliorates ischemia/reperfusion injury in rat cardiac allografts. Circulation. 2001;104:I-202–I-206
  22. Gvozdjakova A, Kucharska J, Mizera S, et al.  Coenzyme Q10 depletion and mitochondrial energy disturbances in rejection development in patients after heart transplantation. Biofactors. 1999;9:301–306
  23. Kemper B. Regulation of cytochrome P450 gene transcription by phenobarbital. Progr Nucl Acid Res Mol Biol. 1998;61:23–64
  24. Raucy JL, Kraner JC, Lasker JM. Bioactivation of halogenated hydrocarbons by cytochrome P4502E1. Crit Rev Toxicol. 1993;23:1–20
  25. Mathews JM, Raymer JH, Etheridge AS, Velez GR, Bucher JR. Do endogenous volatile organic chemicals measured in breath reflect and maintain CYP2E1 levels in vivo?. Toxicol Appl Pharmacol. 1997;146:255–260
  26. Remmer H, Hintze T, Frank H, Muh-Zange M. Cytochrome P-450 oxidation of alkanes originating as scission products during lipid peroxidation. Xenobiotica. 1984;14:207–219
  27. Iida T, Ohta A, Takagi M. Cloning and characterization of an n-alkane-inducible cytochrome P450 gene essential for n-decane assimilation by Yarrowia lipolytica. Yeast. 1998;14:1387–1397
  28. Turgeon DK, Leichtman AB, Lown KS, et al.  P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients. Clin Pharmacol Ther. 1994;56:253–260
  29. el Gamel A, Keevil B, Rahman A, Campbell C, Deiraniya A, Yonan N. Cardiac allograft rejection (Do trough cyclosporine levels correlate with the grade of histologic rejection?). J Heart Lung Transplant. 1997;16:268–274
  30. Akhlaghi F, Keogh AM, Brown KF. Unbound cyclosporine and allograft rejection after heart transplantation. Transplantation. 1999;67:54–59
  31. Nohria A, Ehtisham J, Ramahi TM. Optimum maintenance trough levels of cyclosporine in heart transplant recipients given corticosteroid-free regimen. J Heart Lung Transplant. 1998;17:849–853

☆ Michael Phillips is president of Menssana Research, Inc., and holds patents issued and pending on the breath test employed in this study. None of the other authors has any conflict of interest or financial interest with regard to this article.Supported by a grant from the NHLBI (2R44HL59715).

PII: S1053-2498(03)00354-1

doi: 10.1016/j.healun.2003.07.017

The Journal of Heart and Lung Transplantation
Volume 23, Issue 6 , Pages 701-708 , June 2004

Article Tools

* Image Usage & Resolution